NCT04560790View on ClinicalTrials.gov

Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

July 5, 2022

Study Completion Date

July 5, 2022

Conditions
Viral KeratitisBlindness EyeHerpes Simplex Virus InfectionCornea
Interventions
DRUG

BD111 Adult single group Dose

3-6 Participants will receive a single group dose administered via corneal injection in the study eye.

Trial Locations (1)

200000

Eye & Ent Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Eye & ENT Hospital of Fudan University

OTHER

lead

Shanghai BDgene Co., Ltd.

INDUSTRY

NCT04560790 - Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis | Biotech Hunter | Biotech Hunter